Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management (Q38018571)

27 August 2017

title

Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management (English)

1 reference

27 August 2017

author name string

Guillermo Garcia-Manero

series ordinal

1

1 reference

27 August 2017

publication date

1 July 2012

1 reference

American Journal of Hematology

27 August 2017

published in

1 reference

27 August 2017

volume

87

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

692-701

1 reference

Hypomethylating agents and other novel strategies in myelodysplastic syndromes

27 August 2017

cites work

1 reference

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

21 January 2018

1 reference

Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries

21 January 2018

1 reference

Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system

21 January 2018

1 reference

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

21 January 2018

1 reference

Current concepts in the pathophysiology and treatment of aplastic anemia

21 January 2018

1 reference

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

21 January 2018

1 reference

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

21 January 2018

1 reference

A prognostic score for patients with lower risk myelodysplastic syndrome

21 January 2018

1 reference

Unraveling the molecular pathophysiology of myelodysplastic syndromes

21 January 2018

1 reference

Clinical effect of point mutations in myelodysplastic syndromes

21 January 2018

1 reference

Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis

21 January 2018

1 reference

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

21 January 2018

1 reference

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis

21 January 2018

1 reference

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

21 January 2018

1 reference

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

21 January 2018

1 reference

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

21 January 2018

1 reference

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

21 January 2018

1 reference

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

21 January 2018

1 reference

Targeting immune dysregulation in myelodysplastic syndromes

21 January 2018

1 reference

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

21 January 2018

1 reference

Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome

21 January 2018

1 reference

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

21 January 2018

1 reference

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

21 January 2018

1 reference

Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.

21 January 2018

1 reference

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes

21 January 2018

1 reference

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

21 January 2018

1 reference

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

21 January 2018

1 reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

21 January 2018

1 reference

Future directions for the use of hypomethylating agents

21 January 2018

1 reference

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

21 January 2018

1 reference

Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.

21 January 2018

1 reference

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

21 January 2018

1 reference

High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

21 January 2018

1 reference

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematol

21 January 2018

1 reference

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

21 January 2018

1 reference

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

21 January 2018

1 reference

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

21 January 2018

1 reference

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

21 January 2018

1 reference

Myelodysplastic Syndromes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23264

1 reference

27 August 2017

1 reference